natgillin/translations-raw huggingface dataset:
is independently hydrogen, a C1-4 alkyl, a C3-6 cycloalkyl, phenyl or benzyl or a pharmaceutically acceptable salt thereof. 
Rz je neovisno vodik, C,4alkil, C2.g cikloalkil, fenil ili benzil ili njegova farmaceutski prihvatljiva sol.
and R6 are independently hydrogen, C1-6alkyl, or CR5R6 represents a carbonyl or CR5R6 represents a cyclopropyl; 
i R6 su zasebno vodik, C1-6alkil ili CR5R6 koji predstavlja karbonil ili CR5R6 koji predstavlja ciklopropil;
a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond R2 is not H; 
gdje a, bi c odgovarajuće označavaju, nezavisno jedan od drugoga, jednostruku vezu ili dvostruku vezu, uz uvjet da barem jedan od a, b i c predstavlja dvostruku vezu, i uz uvjet da ako je a jednostruka veza i b je dvostruka veza, tada R, nije H;
The composition of claim 1, wherein the soluble portion of the M.hyo preparation has been treated with protein-A or protein-G prior to being added to the immunogenic composition. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što se supernatant kulture M.hyo obradi proteinom-A ili proteinom-G prije dodavanja u imunogeni pripravak.
The method as claimed in claim 20, in which the agent which binds specifically to the tumor-associated antigen or the part thereof is an antibody binding specifically to said tumor-associated antigen or to said part thereof. 
Postupak prema patentnom zahtjevu 7, naznačen time što je sredstvo koje se vezuje specifično za antigen povezan sa tumorom - antitijelo koje se specifično veže za navedeni antigen povezan sa tumorom.
A pharmaceutical composition comprising at least one antigen binding protein of claim 1, 2, or 3 and pharmaceutically acceptable excipient. 
Farmaceutski sastav sadrži najmanje jedan protein koji veže antigen iz bilo kojeg od patentnih zahtjeva 1-5 i farmaceutski prihvatljivi ekscipijens.
In this case, the lower edges of the lining 114, the membrane 115 and the upper 113, generally designated by the reference numeral 128, are folded and glued under the perforated insole 116 and lie adjacent to the breathable element 121 of the sole 111. 
U tom se slučaju donji rubovi podstave 114, membrane 115 i gornjišta 113, općenito označeni brojčanom referencom 128, presavijaju i lijepe ispod perforiranog unutarnjeg potplata 116 i nalaze se odmah do prozračnog elementa 121 potplata 111.
During fermentation, these fibres are degraded and short chain fatty acids (SCFA) are produced, lowering pH levels and providing an energy source for growth and maintenance of large intestine cells. 
Ta se vlakna tijekom fermentacije razgrađuju i stvaraju masne kiseline kratkih lanaca (short chain fatty acid, SCFA), snizuje se pH i namiče energija za rast i održavanje stanica debelog crijeva.
Process according to claim 29, wherein the fluid is a fire extinguishing agent 
Postupak prema zahtjevu 28, naznačen time da fluid je sredstvo za gašenje požara.
A composition according to any of claims 1 to 7 for use in the treatment or prevention of uterine atony, for example following vaginal delivery of the infant, delivery of the infant by Caesarean section, or for use in the treatment or prevention of uterine atony in a patient who is at risk of developing PPH; and/orfor use in the treatment or prevention of excessive bleeding following vaginal delivery. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju atonije maternice, primjerice nakon vaginalnog porođaja novorođenčeta, porođaja novorođenčeta carskim rezom, ili upotrebi u liječenju ili sprječavanju atonije maternice kod pacijentice koja je u opasnosti od razvoja PPH; i/ili upotrebi u liječenju ili sprječavanju prekomjernog krvarenja nakon vaginalnog porođaja.
Similarly the azido starting materials can also be prepared analogously to route (b) above for preparing the N-benzyl starting materials. 
Na sličan način, azido polazni materijali mogu se također napraviti analogno putu (b) gore za pravljenje N-benzil 30 = polaznih materijala.
administering a second dosage of glyceryl tri-[4-phenylbutyrate] (HPN-100) based on the determination in (c). The method of claim 1 or 4, further comprising a step of determining the upper limit of normal for blood ammonia for the subject. 
Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu prema zahtjevu 1 ili 4, naznačen time da nadalje sadrži korak određivanja gornje granice normale za amonijak u krvi za subjekta.
The magnesia cement of any one of claims 1 to 4, characterized in that it comprises one or more additional ingredients selected from the group consisting of a magnesia hydration retarding agent, a finely grinded hard-burned magnesia, a finely grinded dead-burned magnesia, and a finely grinded fused magnesia. 
Magnezijski cement prema bilo kojem od zahtjeva 1 do 4, naznačen time što sadrži jedan ili više dodatnih sastojaka odabranih od skupine koja je sastoji od agensa za usporavanje hidratacije magnezije, fino usitnjene tvrdo-pečene magnezije, fino usitnjene mrtvo-pečene magnezije 1 fino usitnjene fuzionirane magnezije.
A product for the biological control of phytopathogenic fungi and stimulating plant growth according to one of claims 2 to 5, characterized by containing, in addition to the bacterial cells, the supernatant of the culture with organic matter and substances with antifungal activity among others. 
Proizvod za biološku kontrolu fitopatogenih gljivica i stimuliranje rasta biljaka temeljem jednog od zahtjeva 2 do 5, naznačen time što između ostalog sadrži, osim bakterijskih stanica, supernatant kulture sa organskom tvari 1 supstance sa antifungalnom aktivnošću.
Use of (a) a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient, which is used in combination with (b) at least one other antitumor compound, for the production of an antitumor agent. 
Upotreba (a) spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, kao aktivni sastojak, kojeg se upotrebljava u kombinaciji s (b) najmanje još jednim antitumorskim spojem, naznačena time što su spoj formule [I] i dodatni antitumorski spoj namijenjeni proizvodnji antitumorskog sredstva.
instructions for using the anti-LAG-3 antibody and anti-PD-1 antibody according to claim 4. 
uputstva za primjenjivanje anti-LAG-3 antitijela i anti-PD-1 antitijela u skladu sa patentnim zahtjevom 1.
In addition, the increased endoluminal pressure, linked with the production of gas and associated with predisposing local factors, can promote the occurrence of diverticula which are susceptible to infection and inflammation and which are located exclusively in the colon (Jackson BT. 
Dodatno, povećani endoluminalni tlak povezan sa nastajanjem plina 1 postojećim lokalnim faktorima mogu potaknuti nastajanje divertikula koji su podložni infekcijama i upalama a smješteni su isključivo u kolonu (Jackson BT.
Known organomineral fertilizers are based on lignite and brown coal as the organic component, therefore their use depends on the availability of lignite and brown coal resp. 
Poznata su tako organsko-mineralna gnojiva na osnovi lignita i smeđeg ugljena kao organske komponente, ali je njihova upotreba ograničina sa stajališta raspoloživosti lignita, odnosno smeđeg ugljena.
Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-l-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for use according to claim 1 or 2, wherein the therapeutically effective amount is divided into one, two, three or four daily doses. 
Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema zahtjevu 1 ili 2, naznačen time, da je terapeutski učinkovita količina podijeljena u jednu, dvije, tri ili četiri dnevne doze.
Generally, it can be stated that the locking element 12 preferably consists of a strip which is attached in a recess, in the represented example, thus, the recess 13, in the floor panel 1 and that attachment provisions are present therein, retaining the strip in the recess. 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je element zaključavanja (12) pružen u udubini (13) i time što, je u slobodnom nespojenom stanju, i dalje smješten zajedno sa svojim dijelom za zaključavanje (17) barem djelomice unutar udubine (13).
The aqueous pharmaceutical suspension according to claim 3, wherein the xylitol, sorbitol or sorbitol solution, or maltitol solution is, by weight/volume (g/100 mL), 10% to 20%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola iznosi, težinskifvolumno (g/100 ml), otprilike 10 % do otprilike 20 %.
A method for manufacturing 4-((1R, 3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula I) or a salt thereof, which method comprises conversion of the compound of formula Va in cis -configuration to the compound of formula I, wherein formula I and Va are as follows: 
Postupak proizvodnje 4-((1R,3S)-6-klor-3-fenilmdan-1-i11)-1,2,2-trimetilpiperazina (formula I) ili njegove soli, a postupak obuhvaća pretvorbu spoja formule Va cis-konfiguracije u spoj formule 1, gdje su formula I i Va kako slijedi: (D)
A pharmaceutical tablet or capsule comprising 20 to 300 mg or 30 to 200 mg of a high purity diaminophenothiazinium compound according to claim 8, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Farmaceutska tableta ili kapsula, naznačena time, da obuhvaća od 20 do 300 mg ili od 30 do 200 mg diaminofenotiazinskog spoja visoke čistoće prema bilo kojem od zahtjeva 1 do 8, i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
1 lit of water was added at 0° to 5° C. and the pH adjusted to 2.0 with concentrated hydrochloric acid at 15° to 20° C. Stirred for 0.5 hr and the layers were separated. 
Dodana je 1 litra vode na 0-5 "C te je pH podešen na 2,0 s koncentriranom klorovodičnom kiselinom na 15-20 *C. Miješeno je tijekom 0,5 sata 1 slojevi su bili odijeljeni.
As shown in the embodiment depicted in Figure 11, the members 1104 may be coupled to a ring-shaped ridge 1105. 
Kako je prikazano na ostvarenju na Slici 11, dijelovi 1104 mogu biti spojeni na izbočenje u obliku obruča 1105.
by injection, infusion or inhalation. 
injekcijom, infuzijom ili inhalacijom.
adjusting a methane number of the LNG to a value necessary for the engine by separating a heavy hydrocarbon component from the LNG when the LNG is supplied to the engine through the pump line. 
Postupak obrade ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se, kada se LNG uskladišten u spremniku za teret dovodi u pomoćni motor, teške ugljikovodike kao komponentu odvaja od LNG-a kako bi se podesilo metanski broj LNG-a do vrijednosti potrebne za pomoćni motor.
● aryl; arylalkyl; aryloxy; arylalkoxy; arylalkylamino; arylalkylsulfanyl; heteroaryl; heteroaryloxy whose (hetero)aryl part can be substituted with one or more of amino, halo, alkyl, (poly)haloalkyl, hydroxyalkyl, alkoxy, (poly)haloalkoxy, alkoxycarbonylamino, alkylcarbonyl, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, nitro, cyanoalkyl, or fused with a non aromatic heterocycle; and wherein R9 and R10 can form together with the C atoms to which they are attached an aromatic ring as well as their enantiomers, diastereomers, mixtures thereof and pharmaceutically acceptable salts, tautomers, hydrates and solvates. 
* arila; arilalkil; ariloksi; arilalkoks1; arilalkilamino; arilalkilsulfanila; heteroarila; heteroariloksi čiji (hetero)arilni dio može biti supstituiran s jednim ili više od amino, halo, alkil, (poli)haloalkil, hidroksialkil, alkoksi, (poli)haloalkoksi, alkoksikarbonilamino, alkilkarbonil, alkilsulfanil, alkilsulfinil, alkilsulfonmil, nitro, cijanoalkil, ili kondenziran s nearomatskim heterociklom; i pri čemu R9 i R10 mogu zajedno s atomima ugljika na koje su oni vezani tvoriti aromatski prsten kao i enantiomeri, dijastereomeri, njihovi smjese i farmaceutski prihvatljive soli, tautomeri, hidrati i solvati.
information about a suffix of the last coefficient location generated by performing entropy encoding on a suffix bitstring of the last coefficient location of the transformation block according to bypass mode, 
prijemnik koji je konfiguriran za primanje toka bitova koji uključuje informacije o položaju zadnjeg značajnog koeficijenta u bloku transformacije;
Table 13: Physical characteristics of the final blend 
Datum objave europskog patenta:
For oral administration a daily dose will typically be within the range 10 to 800mg, e.g. 20 to 150 mg per day. 
Kod oralne primjene dnevna doza je u pravilu u rasponu od 10 do 800 mg, primjerice 20 do 150 mg dnevno.
matching (56) said estimated torque-speed transfer function and a torque-speed transfer function computed (55) from said computational model of said borehole equipment (10), and 
- uspoređivanje (56) navedene procijenjene funkcije prijenosa okretnog momenta u brzinu 1 funkcije prijenosa okretnog momenta u brzinu, izračunate (55) 1z navedenog računalnog modela navedene opreme za pravljenje bušotina (10), 1
In some embodiments, the PE functional domain III consists of the sequence of residues 395 to 613 of SEQ ID NO:1. 
Mutirani PE iz zahtjeva 1, naznačen time da se funkcionalna domena III PE-a sastoji od sekvencije ostataka 395- 613 sekvencije SEQ ID NO: 1.
The metal substrate of statement 14, comprising another electroplated metal layer containing embedded luminescent particles of a different composition than the previous embedded luminescent particles. 
Metalna podloga u skladu s patentnim zahtjevom 7, naznačena time što ima drugi galvanizirani metalni sloj, koji sadrži uklopljene luminiscentne čestice drugačijeg sastava nego ranije uklopljene luminiscentne čestice.
wherein the third connection comprises a thread, 
treći spoj (AS3) ima navoj, -
The compound of claim 1 or a salt or polymorph thereof, wherein R3 is -C(O)-NR9-Z3(R10); X3 is absent or lower alkylidene; R9 is hydrogen or lower alkyl; Z3 is absent, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy or carbonylalkoxy); and, R10 is hydrogen, aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloallcyl or heterocyclyl is each optionally substituted by one or more hydroxy, halogen, alkyl (optionally substituted at one or more positions by halogen), alkoxy, carboxy, carbonylalkoxy, carbamoylalkyl or aminosulfonyl. 
Spoj prema zahtjevu 1 ili njegova sol ili polimorf, naznačen time da Rz je -C(O)-NRo-Z(R19); X3 je odsutan ili niži alkiliden; Ry je vodik ili niži alkil; Z; je odsutan, ili alkil (pri čemu je alkil proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi ili karbonilalkoksi); i R,g je vodik, aril, C3-C;, cikloalkil ili heterociklil, pri čemu aril, C;-C,> cikloalkil ili heterociklil je svaki proizvoljno supstituiran sa jednim ili više hidroksi, halogenom, alkilom (proizvoljno supstituiranim u jednom ili više položaja sa halogenom), alkoksi, karboksi, karbonilalkoksi, karbamoilalkilom ili aminosulfonilom.
The synthesis method according to claim 1, wherein the enzymatic hydrolysis reaction is carried out by an esterase obtained from strain AJ3 of Ophiostoma novo - ulmi. 
Postupak sinteze u skladu s patentnim zahtjevom 1, naznačen time, da se reakcija enzimske hidrolize provodi upotrebom esteraze dobivene iz soja AJ3 Ophiostoma novo-u/mi.
The method according to claim 10 wherein the disorder to be treated is a mood disorder that is selected from the group consisting of a depressive disorder and a bipolar disorder. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 14, ili njegove farmaceutski prihvatljive soli, naznačen time što se poremećaj raspoloženja bira iz skupine koju čine depresivni poremećaj i bipolarni poremećaj.
According to the invention the building block of formula (I) can be prepared starting either from compound of general formula (II) or from compound of general formula (III) wherein LG is a suitable leaving group. 
Sukladno izumu gradivni se blokovi formule (T) mogu pripraviti počevši ili od spoja opće formule (IT) ili od spoja opće formule (III) u čemu je OS pogodna odlazna skupina.
or a pharmaceutically acceptable salt thereof. A compound according to claim 1, wherein X1 is selected from the group consisting of H, F, Cl, Br, I, -OT1, -N(T2)(T3), -NHC(=O)T4, nitro, cyano, cyclopropyl and -C1-3alkyl; and X2 and X3 are independently selected from the group consisting of F, Cl, Br and I. 
Spoj prema zahtjevu 1, pri čemu x! je odabran iz skupine koju čine H, FE, CI, Br, I, -OT!, -N(T?X(T*), -NHC(=0)T", nitro, cijano, ciklopropil i -C,;alkil; i X? i X? su neovisno odabrani iz skupine koju čine F, Cl, Br i I.
Holder (1, 21, 31, 41, 51) according to claim 4, in which, on the one hand, the taper (B) is at least 10°, for example 15° or more, and, on the other hand, preferably at most 45°, more preferably at most 30°. 
Držač (1, 21, 31, 41, 51) u skladu s patentnim zahtjevom 4, naznačen time što je, u jednu ruku, suženje (B) najmanje 10°, primjerice 15° ili više, a u drugu ruku, po mogućnosti najviše 45°, poželjnije najviše 30°.
other tumors, which comprise melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, endometrial cancer, head and neck cancer, glioblastoma, malignant ascites, and hematopoietic cancers. 
(D) melanoma, seminoma, teratokarcinoma, osteosarkoma, xenoderoma pigmentosum, keratoktantoma, folikularnog karcinoma štitnjače, Kaposijevog sarkoma, raka endometrija, raka glave i vrata, glioblastoma, malignog ascitesa, ili hematopoetskih rakova.
A capsule according to claim 7, wherein said sealing film made from flexible multilayer film to preserve freshness. 
Kapsula (1) u skladu s patentnim zahtjevom 1, naznačena time što je film za brtvljenje (11) načinjen od fleksibilnog višeslojnog filma kako bi se očuvala svježina.
an interior solution within the liposome, wherein a difference in osmolyte concentration between the interior solution and the exterior solution is greater than 200 mOsm, wherein the difference in osmolyte concentration is the exterior solution osmolyte concentration subtracted from the interior solution osmolyte concentration. 
- <- unutarnje otapalo, koje je sadržano u liposomu, pri čemu je razlika koncentracije osmolita između unutarnjeg i vanjskog otapala (vanjska koncentracija osmolita subtrahirana od unutarnje koncentracije osmolita) iznosi više od 200 mM.
R4y' is hydrogen, C1-4 alkyl, C1-4 fluoroalkyl, C6-10 ar(C1-4)alkyl, the aryl portion of which may be optionally substituted, or an optionally substituted 5- or 6-membered aryl, heteroaryl, or heterocyclyl ring; or 
y’ je vodik, C1-4 alkil, C1-4 fluoroalkil, C6-10 ar(C1-4)alkil, čiji aril dio može biti izborno supstituiran, ili izborno supstituirani 5- ili 6-člani aril, heteroaril ili heterociklil prsten; ili
A method for producing a ternesite clinker, comprising sintering a raw meal mixture, which contains at least sources for CaO, SiO2, and SO3, wherein a temperature during sintering is adjusted in the range of 900 to 1300° C. such that the ternesite clinker has a content of C5S2$ ranging from 20 to 95% by weight and a content of C4(AxF(1-x))3$, with x being 0.1 to 1, of less than 15% by weight, in each case relative to the total weight of the clinker. 
Postupak proizvodnje ternesit klinkera, naznačen time što je sirova mješavina, koja sadrži barem izvore za CaO, SiO», i SO», sinterirana, pri čemu je temperatura tijekom sinteriranja prilagođena na opseg od 900 do 1300%C na način da ternesit klinker ima sastav od C5S2$ opsega od 20 do 95 % težine i sadržaj Cx(A,F-x9)3$, pri čemu je x 0.1 do 1, od O do manje od 15% težine, u svakom slučaju u odnosu na ukupnu težinu klinkera.
optionally followed by a Wittig reaction to generate compounds of Formula L, wherein R23 is selected from the group consisting of —CH3; —CH2CH3; 
Opcijski nakon toga slijedi Wittig reakcija da se dobije spoj od Formule L, naznačeno time, da je R23 odabran iz skupine koja sadrži i
As has already been stated above, separation can also be effected in a plurality of steps, wherein at least one separation step is affected by mechanical machining, which results in the aforementioned contamination due to the swarf which is formed and/or to any aids which are used. 
Kao što je već bilo gore spomenuto, odvajanje se također može provesti u više koraka, pri čemu barem jedan korak odvajanja je mehanička strojna obrada, koja ima za posljedicu gore spomenuto onečišćenje zbog nastalih strugotina i/ili zbog bilo kojeg upotrijebljenog pomoćnog sredstva.
A conjugate according to claim 14 wherein said cell binding agent is chosen from antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, growth factors, nutrient-transport molecules, or any other cell binding molecule or substance. 
Konjugat u skladu s patentnim zahtjevom 3 do 7 naznačen time što se navedeno sredstvo za vezanje na stanicu bira između protutijela ili fragmenta protutijela koji sadrži najmanje jedno vežuće mjesto, limfokina, hormona, čimbenika rasta, molekula za prijenos nutrijenata ili bilo koje druge molekule ili tvari koja se veže na stanicu.
a T cell receptor B-chain comprising at least one, preferably two, more preferably all three of the CDR sequences of a T cell receptor B-chain of SEQ ID NO: x+1 or a variant thereof; wherein x selected from the group consisting of 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 and 
(ii) B-lanac T staničnog receptora koji sadrži sve tri CDR sekvence B-lanca T staničnog receptora od SEK IDBR:x +1; naznačen time, da je x odabran iz skupine sastavljene od 6, 8, 10, 12, 14, 16, 18, 20, 22,24, 26128 i
• bonding a part of the wear resistant particles (15) to the surface (2) with the liquid binder (11), 
. vezanje dijela čestica otpornih na habanje (15) na površinu (2) s tekućim vezivom (11),
Method according to anyone of claims 1 to 8, wherein the concentrator (C) determines whether a remote meter (RM) is enabled to perform the operation of transmitting an amount (L) of consumption related data (MV1, MV2... 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu sabirnik (C) određuje je li daljinskom brojaču (RM) omogućeno provoditi operacije prijenosa količine (L) periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju (MVI1, MV2...
Y is independently hydrogen, halogen, NO2, CN or C1-C10 alkyl; and, Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino. 
X je O, S, S(O), S(O)2, N(R8) ili C(O) Y je neovisno vodik, halogen, NO2, CN ili C1-C10 alkil; te Z je amino, supstituirani ili nesupstituirani alkilamino, supstituirani ili nesupstituirani dialkilamino, supstituirani ili nesupstituirani alkilkarbonilamino.
The process according to Claim 1, wherein in the step (1), 2,4-dichloro-3,5-dinitrobenzotrifluoride is used in an amount of from 0.8 to 1.2 mol in relation to 1 mol of 2-amino-3-chloro-5-trifluoromethylpyridine. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je u koraku (1) korišten 2,4-dikloro-3,5-dinitrobenzotrifluorid u količini od 0.8 do 1.2 mola u odnosu na 1 mol 2-amino-3-kloro-5-trifluorometilpiridina.
The method of claim 1 wherein the graphite moderator core has a damage operation duration beyond which the graphite moderator core becomes damaged, the pre-determined duration of operation being shorter than the core damage operation duration. The method of claim 1 wherein: the fuel salt is a molten fuel salt; 
Postupak prema patentnom zahtjevu 1, naznačen time, da grafitna jezgra moderatora kod oštećenja ima trajanje rada, nakon kojeg grafitna jezgra moderatora postaje oštećenom, kod čega je predodređeno trajanje rada kraće od trajanja rada jezgre kod oštećenja.